The Molecular Imaging and Theranostics Center brings together researchers, clinicians, trainees and external partners to advance discoveries in molecular imaging, radiopharmaceutical development and theranostic innovation. As a university-wide resource at the University of Missouri, MITC provides shared expertise, facilities and support for investigators who want to incorporate state-of-the-art in vivo imaging into basic, translational and early clinical research.

The Molecular Imaging and Theranostics Center fosters collaboration with several key organizations and research centers. These alliances drive innovation in molecular imaging, radiopharmaceuticals, and clinical translation. Below is a detailed breakdown of the partnerships and their roles:

Focus
Production of cGMP radiopharmaceuticals and PET/CT radiotracers
Contribution
Supplies agents for first-in-human trials. Provides radiopharmaceuticals for companion animal studies.
Focus
High-resolution imaging using MRI, PET, and SPECT technologies.
Contribution
Facilitates clinical translation of research outcomes. Enhances imaging capabilities for patient care.
Focus
Clinical trials and translation
Contribution
Bridges the gap between research and patient care. Supports clinical studies for innovative therapies.
Focus
Radiopharmaceutical production and small animal imaging tracers
Contribution
Provides critical resources for preclinical and clinical research. Supports the development of imaging agents.
Focus
Cancer research and patient care.
Contribution
Advances translational oncology through clinical trials. Collaborates on innovative cancer therapies.
Focus
Small animal imagining and cardiovascular disease research.
Contribution
Conducts preclinical studies on cardiovascular health. Develops imaging techniques for heart disease research.